An overview of the published evidence that informs Oprimaze's two-phase design. Every section links to its source studies — and we draw a clear line between what's well established and where research is still maturing.
Hunger-driving hormones rise after weight loss and remain elevated for at least a year — pulling the body back toward its previous weight. Structured appetite support during and after loss is one of the few interventions shown to blunt that response.
Resting metabolic rate drops after sustained weight loss and stays suppressed, meaning the same intake yields weight gain. Maintenance protocols that target metabolic stability outperform diet-only approaches.
Roughly two-thirds of weight lost on injectable therapy returns within 12 months of stopping in controlled trial settings — most of it in the first six months. A structured maintenance phase is the missing piece in most weight programmes.
Published pharmacokinetic studies report intranasal bioavailability of roughly 34–46% for relevant plant compounds, versus 6–19% for oral routes — with onset in minutes rather than tens of minutes.
Every figure on this site is sourced from peer-reviewed published research.